Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report

Ann Oncol. 2010 Mar;21(3):667-668. doi: 10.1093/annonc/mdp563. Epub 2009 Dec 23.

Authors

E Montagna¹, G Cancello², R Torrisi², S Rizzo³, E Scarano², M Colleoni²

Affiliations

¹ Department of Medicine, Research Unit in Medical Senology. Electronic address: emilia.montagna@ieo.it.
² Department of Medicine, Research Unit in Medical Senology.
³ Division of Diagnostic Radiology, European Institute of Oncology, Milan, Italy.

PMID: 20032127
DOI: 10.1093/annonc/mdp563

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism
Breast Neoplasms / pathology
Capecitabine
Carcinoma, Papillary / drug therapy*
Carcinoma, Papillary / metabolism
Carcinoma, Papillary / pathology
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Female
Fluorouracil / administration & dosage
Fluorouracil / analogs & derivatives
Humans
Lapatinib
Middle Aged
Neoplasm Invasiveness
Quinazolines / administration & dosage
Receptor, ErbB-2 / metabolism*
Treatment Outcome

Substances

Quinazolines
Lapatinib
Deoxycytidine
Capecitabine
Receptor, ErbB-2
Fluorouracil